FDA Panel Backs New Obesity Drug

By The Burrill Report: By Michael Fitzhugh

Joseph Krueger submits: This week is a critical time period for Vivus (VVUS) investors, but it should also be interesting for Arena Pharmaceuticals (ARNA) and Orexigen (OREX) investors, as the three companies all have near term FDA panel

By KLLJ Investments: On the morning of May 8th, the Food & Drug Administration (FDA) will release the briefing documents for the May 10th Advisory Committee (AdCom) meeting to discuss the risk and benefit profile of Arena Pharmacueticals' (ARNA) new drug, Lorqess (lorcaserin hydrochloride).

By StockPandit:2012 is so far the best year for the Biotechnology and Drugs industry. So many stocks surged in the last three months based on clinical trial results, U.S. Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, European commission approval, recommendation from independent committees, partnership with big pharmaceuticals, acquisitions and so on. Below is the list of three biotech stocks that are waiting for drug approval for their anti-obesity drug.

Prohost Biotech submits:This Thursday an FDA advisory panel will discuss Arena’s (ARNA) drug Lorqess (lorcaserin) for obesity.

A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill called Qnexa, a drug which the FDA previously rejected due to safety concerns.The ...

The Burrill Report submits: A U.S. Food and Drug Administration advisory panel has voted against expanding the use of GlaxoSmithKline’s (GSK) Avodart, its treatment for enlarged prostate, to include reducing the risk of prostate cancer in men at risk for the disease. The panel voted 14 to 2 against.

The Burrill Report submits: By Michael Fitzhugh, Marie DaghlianArena Pharmaceutical’s (ARNA) shares plunged nearly 40 percent after a U.S. Food and Drug Administration advisory committee rejected its proposed weight loss drug lorcaserin. The reviewers expressed concern that potential risks of long-term use outweighed its benefit of modest weight loss.